Published on 23/12/2025

EU veterinary renewals and post approval obligations

The regulatory landscape for veterinary medicines in the European Union (EU) is complex and requires a comprehensive understanding of the applicable laws and guidelines. This article will provide a step-by-step tutorial on EU veterinary renewals and post-approval obligations, especially focusing on the framework provided by the EU Veterinary Medicines Regulation (VMR). It aims to assist regulatory affairs professionals, quality assurance specialists, and pharmacovigilance teams working in the jurisdictions of the US, UK, and EU.

Understanding EU Veterinary Medicines Regulation

Veterinary medicines within the EU are regulated under the European Veterinary Medicines Regulation (Regulation (EU) 2019/6), which came into effect on January 28, 2022. This regulation aims to ensure the quality, safety, and efficacy of veterinary medicinal products, while also protecting public and animal health. Compliance with this regulation is critical for manufacturers seeking to market their products in Europe.

The VMR establishes a framework for the authorization and post-marketing oversight of veterinary medicines, notably setting strict criteria for the approval process, pharmacovigilance, and the renewal of marketing authorizations.

Step 1: Initial Marketing Authorization (MA) Process

Before discussing renewals and post-approval obligations, it is essential to understand the process that leads to initial Marketing Authorization (MA). This is the cornerstone of regulatory compliance for any veterinary product in the EU.

• Pre-submission Activities: Engage in consultations with competent authorities to determine the regulatory pathway for your product. This includes identifying the appropriate Veterinary Medicinal Product classification and whether a centralized or decentralized procedure applies.
• Preparation of Dossier: The Marketing Authorization Application (MAA) dossier should be compiled according to the guidelines set forth by the EMA. The documentation must include data on quality, safety, efficacy, and environmental risk assessment.
• Submission: Submit the MAA to the relevant authority. Utilize the electronic Common Technical Document (eCTD) format for seamless processing.
• Review and Evaluation: The regulatory authority will conduct a scientific assessment to verify that the product meets the necessary standards. Be prepared to respond to inquiries and potential requests for additional information.

Once granted, the marketing authorization allows you to place your veterinary product on the market, subject to the obligations set forth in the VMR.

Step 2: Understanding Marketing Authorization Duration and Renewal Process

Marketing authorizations are typically granted for a five-year period. It is crucial to begin preparing for renewal well in advance of this expiration date. The renewal process must be initiated at least 90 days prior to the expiry of the marketing authorization.

• Preparation for Renewal: Compile a renewal dossier that may include updates on data related to persistent efficacy, safety, and quality of the veterinary product. This should also encompass any new findings or developments that have emerged since the original authorization.
• Submit Renewal Application: Similar to the initial application, the renewal dossier must be submitted to the regulatory authority and adhere to the eCTD format.
• Assessment by Regulatory Authorities: The authorities will evaluate the renewal application. Ongoing monitoring of the product’s safety and efficacy from the post-marketing phase will also be taken into account.
• Decision Notification: If the renewal request is granted, you will receive notification permitting continued sale in the EU market. Otherwise, you may need to address any conditions or deficiencies highlighted in the review process.

Step 3: Post-Marketing Surveillance and Pharmacovigilance Obligations

Once your veterinary medicine is on the market, compliance with pharmacovigilance obligations is essential to ensure the ongoing safety of the product. Pharmacovigilance involves the collection and evaluation of information related to adverse events, which is critical for maintaining the drug’s market authorization.

• Establishing a Pharmacovigilance System: Develop a robust system that includes establishing standard operating procedures (SOPs) for monitoring, documenting, and reporting adverse reactions. This also must comply with the Good Pharmacovigilance Practices (GVP) set by the EMA.
• Reporting Adverse Reactions: Any adverse events must be reported promptly to the relevant authorities. Timeliness and accuracy are crucial in your reporting obligations.
• Periodic Safety Update Reports (PSURs): Submit PSURs at least once every three years, or as otherwise required. These reports summarize the safety profile, including any incidents of adverse events, and offer a comprehensive overview of the product’s risk-benefit assessment.

Step 4: Compliance with Post-Approval Changes and Variations

During the lifecycle of your veterinary medicine, you may encounter the need to make changes post-approval. This could relate to the manufacturing process, labeling, or formulation. According to the VMR, all variations must be reported to the regulatory authorities.

• Classifying Variations: Variations to a marketing authorization can be classified as type IA, IB, or II, depending on their potential impact on the safety and efficacy of the veterinary medicinal product.
• Submission Process: Submit variations following the guidelines established by the EMA. Ensure that the submission clearly outlines the proposed changes and justifications.
• Awaiting Authority Response: Depending on the classification of the variation, the regulatory body will assess the submission and provide feedback. Some variations might require additional documentation or studies.

Step 5: Final Considerations for EU Veterinary Medicines Regulation Consulting Services

Given the intricacies involved in navigating the EU veterinary medicines regulatory environment, many organizations opt for EU veterinary medicines regulation consulting services. These services can streamline the process, ensure compliance, and avoid potential pitfalls.

• Choosing the Right Consultant: When seeking consulting services, look for firms that demonstrate extensive experience with the EU and have a proven track record. Verify their familiarity with FDA CVM and EMA veterinary regulations.
• Collaborative Approach: Opt for consulting services that offer a collaborative framework where your team’s expertise is combined with the consultant’s regulatory knowledge.
• Ongoing Support: Choose a consulting service that provides not just initial submission assistance but also ongoing support with renewals, variations, and pharmacovigilance.

Conclusion

Successfully navigating the renewal and post-approval obligations within the framework of the EU Veterinary Medicines Regulation is essential for sustained market presence and compliance for veterinary products. By understanding the nuances of the process, which includes initial marketing authorization, renewal procedures, pharmacovigilance obligations, and regulatory variations, organizations can effectively manage their product’s lifecycle while ensuring the safety of the veterinary market.

For additional insights, consider delving into the EMA’s official guidelines related to veterinary medicines or referencing the FDA Center for Veterinary Medicine (CVM) for regulatory updates and best practices.